Cell-Surface SRC Finding Opens a Preclinical Cancer Target

Researchers at the University of California, San Francisco have identified an unexpected feature on some cancer cells: SRC, a protein kinase normally associated with the inside of cells, can become exposed on the outer membrane.

The finding matters because antibodies and engineered immune therapies can more readily reach a surface target than an intracellular one. The team reported the mechanism and early targeting experiments in Science. The work is a target-discovery study, not a clinical trial.

UCSF said the target could be relevant to as many as half of tumours. That is a research projection based on the patterns examined, not a measured prevalence across all people with cancer.

SRC Reached the Surface Through Cellular Disposal

The researchers studied cancer cells grown in the laboratory and traced SRC through an overactive disposal pathway. In rapidly dividing cells, waste-containing compartments can fuse with the cell membrane instead of completing normal recycling. That process can leave SRC and other N-myristoylated proteins exposed on the cell surface.

The team reported surface SRC in models involving bladder, colorectal, breast and pancreatic cancer. It also detected the protein on patient-derived bladder tumour cells while not detecting it in the healthy bladder tissue or immune cells examined. Those comparisons support selectivity in the tested samples, but they do not prove that every healthy tissue is free of the target.

This distinction is crucial for immunotherapy. A target can be biologically interesting yet unsafe if an antibody also binds an essential healthy organ. Broader tissue mapping and independent replication are therefore required before a human dose can be justified.

Antibodies Worked in Preclinical Models

The group developed antibodies aimed at exposed SRC. In mice carrying implanted human tumour cells, radioactive antibody constructs accumulated in tumours. Other engineered antibodies helped immune cells recognize and kill cancer cells, and the UCSF account reported tumour shrinkage in mice.

These experiments show that the surface protein can be reached and used as a targeting handle in the tested models. They do not show that a therapy is effective in people. Mouse xenografts cannot reproduce the full diversity of human tumours, immune systems, previous treatments or toxicity.

UCSF licensed antibodies and related molecules to Inversion Therapeutics for further development. That commercial step may support additional testing, but licensing is not regulatory approval and does not establish a treatment timeline.

Solid Tumours Need Selective Targets

Some blood-cancer immunotherapies can use markers that are consistently accessible on malignant cells. Solid tumours are harder because target expression can vary within the same tumour and overlap with healthy tissue. A surface-exposed protein associated with tumour biology is therefore attractive, but it must clear a high safety bar.

Kathleen Yates of the Broad Institute, who was not involved in the work, told STAT that the result was provocative while stressing that its translational impact remains unknown. That is the appropriate boundary. The study established a mechanism and two preclinical targeting approaches; it did not compare a new therapy with current cancer treatment in patients.

Claims about pancreatic or colorectal standards changing within a decade are premature. Researchers still need to define which tumours display enough surface SRC, whether expression changes over time, whether normal tissues display low levels, and whether an antibody can reach tumours without damaging healthy cells.

The Discovery Earns Tests, Not a Treatment Promise

The paper's strongest contribution is conceptual. It shows that cellular location is not fixed and that proteins assumed to be inaccessible may become visible through tumour-associated disposal pathways. The same method may reveal other surface targets.

It does not justify blaming earlier cancer deaths on scientists for failing to notice SRC, nor does it show that regulators or drug costs are blocking a ready treatment. The experimental agents have not yet reached the stage where human benefit, adverse effects or price can be measured.

A surprising target becomes medically important only after selectivity survives broader tissue testing and benefit survives human trials. The UCSF team has supplied a plausible mechanism and preclinical tools. The next honest milestone is reproducible safety and activity, not a countdown to standard care. Treating that distinction as caution rather than pessimism is how cancer research avoids turning a useful biological result into false hope.